Pembrolizumab plus Chemotherapy in Advanced Triple-Negative …
WEBJul 20, 2022 · Pembrolizumab monotherapy has shown durable antitumor activity in advanced triple-negative breast cancer, 6-9 particularly as first-line therapy, with improved clinical responses observed among...
FDA approves pembrolizumab for high-risk early-stage triple …
WEBOn July 26, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy...
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of ... - Merck
WEBJul 27, 2021 · FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery. Save. July 27, 2021 6:30 am ET.
FDA Grants Full Approval to Pembrolizumab for Select Patients
WEBMar 29, 2023 · The FDA has granted full approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability–high (MSI-H) or ...
Pembrolizumab for Advanced Triple-Negative Breast Cancer
WEBAug 9, 2022 · Adding the immunotherapy drug pembrolizumab (Keytruda) to chemotherapy can help some patients with advanced triple-negative breast cancer live longer than if they received chemotherapy alone, new results from a clinical trial show.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined …
WEBMay 5, 2021 · KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test.
FDA approves pembrolizumab combination for the first-line …
WEBOn October 13,2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for patients with persistent,...
FDA approves pembrolizumab with chemotherapy for HER2 …
WEBOn November 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of...
Pembrolizumab in the Treatment of Breast Cancer
WEBJul 20, 2022 · In this issue of the Journal, Cortes et al. 1 report that pembrolizumab — a breakthrough therapeutic treatment for patients with advanced triple-negative breast cancer — combined with...
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab …
WEBDec 15, 2023 · Enfortumab vedotin in combination with pembrolizumab is being investigated in an extensive program in multiple stages of urothelial cancer, including two Phase 3 clinical trials in MIBC in EV-304 (NCT04700124, also known as KEYNOTE-B15) and EV-303 (NCT03924895, also known as KEYNOTE-905). The use of enfortumab vedotin in combination with ...